RxDoctor Payments Data

Liuber Carballar Alberteries, MD

Internal Medicine · Tampa, FLNPI 1538698188

Payments from drug & device makers

$3,821in general payments, 2019–2025

Across 142 payments — averaging $26.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$582
  • Bayer$370
  • Boehringer Ingelheim$296
  • Amgen$193
  • Kowa Pharmaceuticals America, Inc.$156
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,821100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,821 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$15,512
Medicare patients
34
Services billed
129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$75,241
TrulicityDulaglutide41$43,792
FarxigaDapagliflozin Propanediol63$41,579
EliquisApixaban33$40,036
MounjaroTirzepatide26$29,151
JardianceEmpagliflozin17$13,840
LinzessLinaclotide16$10,055
SymbicortBudesonide/Formoterol Fumarate11$5,619
Sucralfate41$5,098
Advair HfaFluticasone Propion/Salmeterol13$4,547
Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm16$3,394
Pimecrolimus13$3,158
Diclofenac Sodium117$3,120
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$2,884
Celecoxib132$2,695

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$582$75,24171 claims
Lilly USA, LLCTrulicity, Mounjaro$117$72,94367 claims
AstraZenecaFarxiga, Symbicort$1,206$47,19874 claims
PfizerEliquis$114$40,03633 claims
Boehringer IngelheimJardiance$296$13,84017 claims
AbbVieLinzess$71$10,05516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →